Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹60,210 Cr
P/E Ratio
27.96
P/B Ratio
4.96
Industry P/E
37.25
Debt to Equity
0.12
ROE
18.74 %
ROCE
19.52 %
Div. Yield
0.79 %
Book Value
1014.82
EPS
180.92
CFO
₹9,159.70 Cr
EBITDA
₹13,721.36 Cr
Net Profit
₹10,726.22 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Alkem Laboratories
| -10.66 | -0.38 | 0.22 | 6.62 | 14.30 | 12.98 | -- |
|
BSE Healthcare
| -7.27 | -1.01 | -0.76 | 19.87 | 19.29 | 22.12 | 9.77 |
|
BSE Mid Cap
| -8.32 | 0.34 | -0.44 | 3.84 | 19.86 | 29.98 | 15.08 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Alkem Laboratories
| 10.04 | 73.15 | -17.09 | 22.82 | 40.49 | 3.79 | -12.43 |
|
BSE Mid Cap
| 25.84 | 45.53 | 1.38 | 39.18 | 19.87 | -3.05 | -13.31 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 29,705.00 | 63,212.21 | 47.37 | 36.97 | |
| 311.85 | 37,458.72 | 46.57 | 3.88 | |
| 2,802.70 | 47,502.30 | 55.29 | 49.5 | |
| 1,419.00 | 35,968.92 | 49.31 | 12.83 |
How did MFs fare as anchor investors?
4 min read•By Kumar Shankar Roy
Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active... pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. Alkem Laboratories Limited was incorporated in 1973 and is headquartered in Mumbai, India. Read more
Incorporated
1973
Chairman
Basudeo N Singh
Managing Director
Sandeep Singh
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Alkem Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Alkem Laboratories Ltd stood at ₹ 17,117 Cr as on 31-Dec-24
The share price of Alkem Laboratories Ltd is ₹5,033.50 (NSE) and ₹5,035.75 (BSE) as of 25-Apr-2025 IST. Alkem Laboratories Ltd has given a return of 14.3% in the last 3 years.
Alkem Laboratories Ltd has a market capitalisation of ₹ 60,210 Cr as on 25-Apr-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Alkem Laboratories Ltd is 4.96 times as on 25-Apr-2025, a 4% discount to its peers’ median range of 5.15 times.
The P/E ratio of Alkem Laboratories Ltd is 27.96 times as on 25-Apr-2025, a 25% discount to its peers’ median range of 37.25 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Alkem Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Alkem Laboratories Ltd.
Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. Alkem Laboratories Limited was incorporated in 1973 and is headquartered in Mumbai, India.
The prominent promoters of Alkem Laboratories Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Sarandhar Singh* (please refer notes) |
19.42%
|
|
Basudeo Narain Singh |
7.27%
|
|
Mritunjay Kumar Singh |
6.42%
|
|
Madhurima Singh& (please refer notes) |
6.18%
|
The chairman of the company is Basudeo N Singh, and the managing director is Sandeep Singh.
There is no promoter pledging in Alkem Laboratories Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
63,212
|
|
|
47,502
|
|
|
37,459
|
|
|
35,969
|
| Alkem Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
19.84
|
|
Operating margin(%)
|
17.2
|
|
Net Margin(%)
|
16.66
|
|
Dividend yield(%)
|
0.79
|
Yes, TTM profit after tax of Alkem Laboratories Ltd was ₹2,153 Cr.
₹-167.70
(
